News

This approval substantially broadens the company’s treatment indications for the Powerlink system, which is used in the minimally invasive treatment of abdominal aortic aneurysms (AAA). The Powerlink XL

Mr Blyth has also been retained as a consultant. In this capacity he will provide strategic guidance in late-stage development and commercialization tactics. Mr Blyth has recently retired

In the trial’s Simon two-stage design, 21 patients with non-small cell lung cancer have been enrolled in Stage A of the study. The trial may be expanded to

The National Surgical Adjuvant Breast and Bowel Project’s (NSABP) decision to continue the trial was based on a recommendation from an independent data monitoring committee (DMC) after a

The company’s initial investors, Flagship Ventures, Polaris Venture Partners and Flybridge Capital Partners were joined by new investors Partners Healthcare and In-Q-Tel in the round. T2 Biosystems has

The agreement represents the first occasion of services being offered through Innovent Oncology, which will work with Rocky Mountain Cancer Centers (RMCC) to support Colorado Public Employees’ Retirement

Under the agreement, Hewlett-Packard Company (HP) will license its intellectual property to Home Dialysis Plus (HD+) in return for royalty payments. HD+ will develop, manufacture and sell the

This agreement expands InteGreat’s existing agreement with Nuance, giving InteGreat the ability to provide its clients with Dragon Medical 10, a real-time medical speech recognition software. Dragon Medical

Under the terms of the agreement, Valeant received an upfront payment of $125 million from GlaxoSmithKline (GSK). Valeant develops, manufactures and markets a broad range of pharmaceutical products